CliffBio
small molecule

VAZALORE

ASPIRIN

Loss of exclusivitySeptember 2032latest FDA-listed patent expiry
CompanyPLx Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameVAZALORE
Active ingredientASPIRIN
Strength325MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2013
Marketing statusOTC

Listed patents

PatentExpiresType
9226892September 2032use U-1732
10786444September 2032use U-3559
10646431September 2032product
9216150September 2032product

More from PLx Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.